DenmarkDenmark

Danish firms attractive for investors

12.05.2006

Vaterløse/Hørsholm - Three Danish biopharmaceutical companies have attracted several million euros of investment which will allow them to further the clinical development of their drug candidates.
Hørsholm-based biopharmaceutical company Santaris Pharma A/S has raised Euro40 million through a private investment round made by an international syndicate of life sciences venture investors from the Netherlands, Germany, Switzerland, Denmark and France. The proceeds of the financing will be used to fund continued development of drug candidates based on Locked Nucleic Acid (LNA), an RNA antagonist to Bcl-2, currently in an international Phase I/II trial in patients with chronic lymphocytic leukaemia. The funds will enable the start of clinical studies with other RNA antagonists. The company expects to have a sufficient financial base until mid-2008. Furthermore, the company has announced a new MicroRNA cancer research collaboration with the University of Copenhagen, selected by the Danish Advanced Technology Foundation out of a total of more than 130 applications seeking support of Euro1.3 million.
7TM Pharma A/S, a spin-off from the University of Copenhagen, also has succeeded in raising private capital. The drug development company has closed a Euro19 million Series C financing round and, with this, the company will further develop two lead anti-obesity agents based on targeting 7TM receptors as well as to initiate other drug candidates emerging from this technology.
Vaterløse-based company Egalet A/S has raised a total amount of Euro23.5 million in a private placement led by Finish and Danish investors. The new capital shall help the company to boost clinical studies of their drug candidates targeting heart diseases and pain management.

DenmarkDenmark

19.08.2011

Bagsværd – Net profit at Denmark’s Novo Nordisk A/S ballooned in the first six months of 2011, and the firm has raised guidance for the full year results. Sales rose by 9%, from DKK29.1bn to DKK31.7bn, while reported net profit...

DenmarkDenmark

15.08.2011

Copenhagen – Driven by strong sales, Danish drugmaker Lundbeck A/S reported hefty QII/2011 profits, and says it is now expecting full-year results at the upper end of its guided range. Operating profit rose to DKK1.1bn in the...

DenmarkDenmark

12.08.2011

Copenhagen - All is well in Denmark - for now. Danish Drugmaker Lundbeck reported excellent profits in the second quarter but announced its intention to prepare for deep cuts in research. 175 jobs in Denmark and the US (12.5% of...

DenmarkDenmark

06.06.2011

Kvistgaard – Bavarian Nordic A/S of Denmark has raised DKK698m (EUR94m)through a rights issue to fund development of its prostate cancer vaccine Prostvac. A total of 12.9 million shares were sold at DKK54. The company announced...

DenmarkDenmark

12.04.2011

Kvistgaard – Net loss at Danish biopharmaceutical company Bavarian Nordic A/S increased to DKK390m from DKK266m in the previous year, even though revenue grew to DKK314m, up from DKK75m in 2009. Bavarian Nordic’s lead product is...

DenmarkDenmark

09.04.2011

Copenhagen – Despite recent setbacks, Danish TopoTarget A/S still has hopes for its histone deacetylase (HDAc) blocker belinostat (PXD01). The cytotoxic compound for treating lymphoma and solid tumours has failed to show...

Displaying results 11 to 20 out of 194

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-denmark/browse/1/article/danish-firms-attractive-for-investors.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR35.3%
  • CO.DON3.14 EUR28.2%
  • FORMYCON8.20 EUR16.6%

FLOP

  • CYTOS0.18 CHF-30.8%
  • EVOTEC3.10 EUR-15.8%
  • 4SC1.04 EUR-15.4%

TOP

  • SANTHERA86.95 CHF2112.5%
  • PAION3.22 EUR228.6%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.4%
  • 4SC1.04 EUR-45.0%
  • MOLOGEN6.60 EUR-44.0%

No liability assumed, Date: 30.09.2014


Current issue

All issues

Product of the week

Products